Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study
Abstract Apatinib is a novel antiangiogenic agent that targets vascular endothelial growth factor 2. The aim of our study was to explore the efficacy and safety of apatinib in the treatment of patients with recurrence or metastasis (R/M) inoperable head and neck squamous cell carcinoma (HNSCC). This...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-20272-x |
| _version_ | 1798044499411206144 |
|---|---|
| author | Zijing Liu Zhuangzhuang Zheng Lihua Dong Xiao Guo Xiaojing Jia Jianfeng Wang Lingbin Meng Xiangyan Cui Xin Jiang |
| author_facet | Zijing Liu Zhuangzhuang Zheng Lihua Dong Xiao Guo Xiaojing Jia Jianfeng Wang Lingbin Meng Xiangyan Cui Xin Jiang |
| author_sort | Zijing Liu |
| collection | DOAJ |
| description | Abstract Apatinib is a novel antiangiogenic agent that targets vascular endothelial growth factor 2. The aim of our study was to explore the efficacy and safety of apatinib in the treatment of patients with recurrence or metastasis (R/M) inoperable head and neck squamous cell carcinoma (HNSCC). This multi-center retrospective study analyzed 53 cases of recurrent or metastatic inoperable HNSCC who had progressed or recurred after undergoing standard radiotherapy, chemotherapy, and immunotherapy treated with apatinib from March 2017 to August 2021. Patients continued apatinib until the time of disease progression or onset of intolerable adverse events. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), and disease control rate (DCR) and incidence of adverse events. Univariable and multivariable analyses were performed to determine prognostic factors. The main adverse events were counted, and the severity of the adverse reactions was evaluated. Fifty-three patients with recurrent or metastatic inoperable R/M HNSCC who had progressed or recurred after standard radiotherapy, chemotherapy, and immunotherapy were included. The ORR was 15.1%, and the DCR was 86.8%. The median PFS was 4.4 months (95% confidence interval [CI] 3.7–5.0 months) and the median OS was 6.6 months (95% CI 5.3–7.9 months). The number of apatinib lines was an influencing factor for both PFS and OS, and the Eastern Cooperative Oncology Group (ECOG) score, tumor differentiation, and apatinib duration were only the influencing factors for OS. Of these, only the ECOG score was an independent predictor of OS. The most common adverse reactions were hypertension (39.6%), hand-foot syndrome (32.1%), fatigue (32.1%), oral ulcers (28.3%), and nausea and vomiting (20.8%). Most adverse reactions were grade 1 or 2. Apatinib mesylate has good efficacy for recurrent/metastatic inoperable HNSCC as second-line and above-line treatment. ECOG score was an independent prognostic factors of OS in patients who were treated with apatinib. In addition, the adverse effects of apatinib mesylate were relatively mild. |
| first_indexed | 2024-04-11T23:05:03Z |
| format | Article |
| id | doaj.art-3e7059564d204c0e9d7d73056abe3e6f |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T23:05:03Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-3e7059564d204c0e9d7d73056abe3e6f2022-12-22T03:58:02ZengNature PortfolioScientific Reports2045-23222022-10-0112111210.1038/s41598-022-20272-xEfficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center studyZijing Liu0Zhuangzhuang Zheng1Lihua Dong2Xiao Guo3Xiaojing Jia4Jianfeng Wang5Lingbin Meng6Xiangyan Cui7Xin Jiang8Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin UniversityJilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin UniversityJilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin UniversityDepartment of Radiation Oncology, Jilin Cancer HospitalDepartment of Radiation Oncology, The Second Hospital of Jilin UniversityDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin UniversityDepartment of Hematology and Medical Oncology, Moffitt Cancer CenterDepartment of Otolaryngology-Head and Neck Surgery, The First Hospital of Jilin UniversityJilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin UniversityAbstract Apatinib is a novel antiangiogenic agent that targets vascular endothelial growth factor 2. The aim of our study was to explore the efficacy and safety of apatinib in the treatment of patients with recurrence or metastasis (R/M) inoperable head and neck squamous cell carcinoma (HNSCC). This multi-center retrospective study analyzed 53 cases of recurrent or metastatic inoperable HNSCC who had progressed or recurred after undergoing standard radiotherapy, chemotherapy, and immunotherapy treated with apatinib from March 2017 to August 2021. Patients continued apatinib until the time of disease progression or onset of intolerable adverse events. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), and disease control rate (DCR) and incidence of adverse events. Univariable and multivariable analyses were performed to determine prognostic factors. The main adverse events were counted, and the severity of the adverse reactions was evaluated. Fifty-three patients with recurrent or metastatic inoperable R/M HNSCC who had progressed or recurred after standard radiotherapy, chemotherapy, and immunotherapy were included. The ORR was 15.1%, and the DCR was 86.8%. The median PFS was 4.4 months (95% confidence interval [CI] 3.7–5.0 months) and the median OS was 6.6 months (95% CI 5.3–7.9 months). The number of apatinib lines was an influencing factor for both PFS and OS, and the Eastern Cooperative Oncology Group (ECOG) score, tumor differentiation, and apatinib duration were only the influencing factors for OS. Of these, only the ECOG score was an independent predictor of OS. The most common adverse reactions were hypertension (39.6%), hand-foot syndrome (32.1%), fatigue (32.1%), oral ulcers (28.3%), and nausea and vomiting (20.8%). Most adverse reactions were grade 1 or 2. Apatinib mesylate has good efficacy for recurrent/metastatic inoperable HNSCC as second-line and above-line treatment. ECOG score was an independent prognostic factors of OS in patients who were treated with apatinib. In addition, the adverse effects of apatinib mesylate were relatively mild.https://doi.org/10.1038/s41598-022-20272-x |
| spellingShingle | Zijing Liu Zhuangzhuang Zheng Lihua Dong Xiao Guo Xiaojing Jia Jianfeng Wang Lingbin Meng Xiangyan Cui Xin Jiang Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study Scientific Reports |
| title | Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study |
| title_full | Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study |
| title_fullStr | Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study |
| title_full_unstemmed | Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study |
| title_short | Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study |
| title_sort | efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma a retrospective multi center study |
| url | https://doi.org/10.1038/s41598-022-20272-x |
| work_keys_str_mv | AT zijingliu efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT zhuangzhuangzheng efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT lihuadong efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT xiaoguo efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT xiaojingjia efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT jianfengwang efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT lingbinmeng efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT xiangyancui efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy AT xinjiang efficacyandsafetyofapatinibinpatientswithrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivemulticenterstudy |